Challenges in prescribing DOACs for stroke prevention in AF
Video navigation menu
Use of correct dosing of DOACs 00:30
Underuse of DOACs 03:08
Antidotes for DOACs 04:33
Should all AF patients on VKA, without contra-indication for DOACs, be switched to a DOAC?
- Yes
- No
Faculty
Prof. Freek Verheugt, cardiologist, Amsterdam, The Netherlands
John Eikelboom, Associate Professor in the Department of Medicine at McMaster University, Hamilton, Ontario, Canada
Disclosures
This recording was independently developed under auspices of PACE-cme and funded by an unrestricted grant provided by Boehringer Ingelheim. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: